1325 AVENUE OF AMERICAS, NEW YORK, NY
Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors
Announces First Quarter 2026 Financial Results and Provides Corporate Update
Announces Full Year 2025 Financial Results and Provides Corporate Update
Securities Purchase Agreement - Brainstorm Cell Therapeutics Raises $1M
Brainstorm Cell Therapeutics Enters $1M Securities Purchase Agreement
Brainstorm Cell Therapeutics Inc. Issues Promissory Notes Totaling $94,300
Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Brainstorm Cell Therapeutics Enters $182,400 Securities Purchase Agreement
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
S-1
RW
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload